78 related articles for article (PubMed ID: 3376613)
1. [Protein studies in cystic and peritoneal fluids of ovarian tumors with special reference to CEA].
Briese V; Strache RR; Voss P; Kunze M; Büttner HH
Zentralbl Gynakol; 1988; 110(5):291-7. PubMed ID: 3376613
[TBL] [Abstract][Full Text] [Related]
2. [CEA determination in aspired fluid of cystic ovarian tumors and ovarian cysts and in ascites and serum samples of patients with ovarian tumors].
Kunze M; Büttner HH; Strache RR; Voss P; Briese V; Schrodt U
Zentralbl Gynakol; 1988; 110(16):1006-12. PubMed ID: 3188713
[TBL] [Abstract][Full Text] [Related]
3. Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer.
Wahlberg K; Høyer-Hansen G; Casslén B
Cancer Res; 1998 Aug; 58(15):3294-8. PubMed ID: 9699658
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors.
Artini PG; Ruggiero M; Monteleone P; Carpi A; Cristello F; Cela V; Genazzani AR
Biomed Pharmacother; 2008; 62(6):373-7. PubMed ID: 18037256
[TBL] [Abstract][Full Text] [Related]
5. Comparison of biochemical markers between benign and malignant ovarian cysts.
Knight JA; Wu JT; Miya T; Knight DP
Clin Physiol Biochem; 1986; 4(2):130-5. PubMed ID: 3516514
[TBL] [Abstract][Full Text] [Related]
6. Higher levels of soluble E-cadherin in cyst fluid from malignant ovarian tumours than in benign cysts.
Sundfeldt K; Ivarsson K; Rask K; Haeger M; Hedin L; Brännström M
Anticancer Res; 2001; 21(1A):65-70. PubMed ID: 11299791
[TBL] [Abstract][Full Text] [Related]
7. Peritoneal fluid and HCG influence on steroid production from ovarian tumor tissue, in vitro.
Ridderheim M; Mählck CG; Selstam G; Stendahl U; Bäckström T
Anticancer Res; 1994; 14(5A):1753-8. PubMed ID: 7531411
[TBL] [Abstract][Full Text] [Related]
8. A study of cyst fluid and plasma carcinoembryonic antigen in patients with cystic ovarian neoplasms.
van Nagell JR; Pletsch QA; Goldenberg DM
Cancer Res; 1975 Jun; 35(6):1433-7. PubMed ID: 805659
[TBL] [Abstract][Full Text] [Related]
9. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
[TBL] [Abstract][Full Text] [Related]
10. Calgranulins in cystic fluid and serum from patients with ovarian carcinomas.
Ott HW; Lindner H; Sarg B; Mueller-Holzner E; Abendstein B; Bergant A; Fessler S; Schwaerzler P; Zeimet A; Marth C; Illmensee K
Cancer Res; 2003 Nov; 63(21):7507-14. PubMed ID: 14612552
[TBL] [Abstract][Full Text] [Related]
11. Proliferation tissue polypeptide antigen distinguishes malignant mucinous cystadenocarcinomas from benign cystic tumors and pseudocysts.
Yang JM; Southern JF; Warshaw AL; Lewandrowski KB
Am J Surg; 1996 Jan; 171(1):126-9; discussion 129-30. PubMed ID: 8554126
[TBL] [Abstract][Full Text] [Related]
12. A comparative analysis of pancreas cyst fluid CEA and histology with DNA mutational analysis in the detection of mucin producing or malignant cysts.
Sreenarasimhaiah J; Lara LF; Jazrawi SF; Barnett CC; Tang SJ
JOP; 2009 Mar; 10(2):163-8. PubMed ID: 19287110
[TBL] [Abstract][Full Text] [Related]
13. Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
McKenney JK; Soslow RA; Longacre TA
Am J Surg Pathol; 2008 May; 32(5):645-55. PubMed ID: 18344868
[TBL] [Abstract][Full Text] [Related]
14. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
Ayhan A; Guven S; Guven ES; Kucukali T
Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of serum alpha-beta A immunoreactive inhibin and tumor-associated antigens CA125 and CEA in ovarian cancer.
Phocas I; Sarandakou A; Sikiotis K; Rizos D; Kalambokis D; Zourlas PA
Anticancer Res; 1996; 16(6B):3827-31. PubMed ID: 9042265
[TBL] [Abstract][Full Text] [Related]
16. Clinical factors and biomarkers in ovarian tumors development.
Vrabie CD; Petrescu A; Waller M; Dina I
Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions.
Slipicevic A; Øy GF; Askildt IC; Holth A; Hellesylt E; Flørenes VA; Davidson B
Hum Pathol; 2009 Apr; 40(4):527-37. PubMed ID: 19121847
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy.
Hazelton D; Nicosia RF; Nicosia SV
Clin Cancer Res; 1999 Apr; 5(4):823-9. PubMed ID: 10213218
[TBL] [Abstract][Full Text] [Related]
19. [Usefulness of CEA, CA 15-3 and CA 125 tumor markers in the differential diagnostics of peritoneal effusion].
Kiluk MS; Rółkowski R; Zawadzki RJ; Wojtukiewicz MZ
Pol Merkur Lekarski; 2002 Oct; 13(76):298-301. PubMed ID: 12557435
[TBL] [Abstract][Full Text] [Related]
20. Carcinoembryonic antigen in women with isolated pelvic masses. Clinical utility?
Roman LD; Muderspach LI; Burnett AF; Morrow CP
J Reprod Med; 1998 May; 43(5):403-7. PubMed ID: 9610461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]